What Oryon Cell Therapies does

Oryon Cell Therapies is a privately held, clinical-stage biotechnology company headquartered in Belmont, Massachusetts, founded in 2020 by Ole Isacson, M.D., Ph.D. (Harvard Medical School professor and founding director of the Neuroregeneration Research Institute at McLean Hospital) and Nikola Kojic, M.D., Ph.D. The company is developing an autologous neuron replacement therapy for Parkinson's disease in which patient-derived blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons that are then surgically implanted into the post-commissural putamen. The autologous design is intended to eliminate the need for chronic immunosuppression, and the unilateral implantation approach used in early cohorts provides an internal control to address placebo effects.

The lead program is in an ongoing Phase 1b/2a clinical trial at Brigham & Women's Hospital/Harvard Medical School in collaboration with the Neuroregeneration Institute at McLean Hospital (Mass General Brigham). Interim data from the first five participants, reported in March 2026, showed 29%-62% reductions in OFF-state MDS-UPDRS Part III motor scores at 6-18 months, sustained improvement beyond six months, no serious adverse events, and DaT-SPECT imaging evidence of greater than a five-fold increase in dopaminergic signal in the transplanted putamen of one participant. Several participants also showed reduced levodopa equivalent daily dose, suggesting decreased dependence on dopamine-replacement medication.

Oryon is pre-revenue and has raised approximately $42 million in total equity and grant funding, including a $21 million Series A tranche closed in March 2026 co-led by Neuro.VC and Byers Capital. The company has no commercial product, no disclosed pricing, and no manufacturing-scale commercial operations; revenue, if any, would only follow regulatory approval and commercialization of the autologous cell therapy. Its go-to-market model is currently oriented around clinical trial execution at academic medical centers, scientific conference presentations, and peer-reviewed publications, with future commercialization expected to target movement disorder specialists at major US academic medical centers. The company had 1-10 employees as of the most recent reporting.

Name

Oryon Cell Therapies

Legal name

Oryon Cell Therapies

Website

https://oryoncelltherapies.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Oryon Cell Therapies is a clinical-stage biotechnology company developing an autologous dopaminergic neuron replacement therapy for Parkinson's disease, derived from patient iPSCs and implanted into the putamen, currently in a Phase 1b/2a trial at Brigham & Women's Hospital.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Autologous cell therapy
• Neuron replacement therapy
• Parkinson's disease treatment
• Regenerative medicine
• IPSC-derived neurons

Headquarters

HQ city

Belmont

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Future Therapeutic Product Sales: Pre-revenue clinical-stage biotech company. Anticipated future revenue from commercialization of autologous neuron replacement therapy for Parkinson's disease following regulatory approval. Revenue model will likely involve selling cell therapy products directly to healthcare providers and academic medical centers.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Oryon Cell Therapies develops an autologous neuron replacement therapy in which a patient's own blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons for implantation into the putamen to restore motor function in Parkinson's disease patients. The product eliminates the need for chronic immunosuppression and is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital.

Product overview

Oryon Cell Therapies is a clinical-stage biotechnology company developing a single lead product - an autologous dopaminergic neuron replacement therapy for Parkinson's disease. The therapy involves deriving induced pluripotent stem cells (iPSCs) from the patient's own blood cells, differentiating them into midbrain dopaminergic neurons using proprietary methods, and implanting them directly into the putamen region of the brain to restore dopaminergic function and motor control. The company's technology emerged from 30 years of scientific advances in stem cell biology and neurosurgical techniques, including foundational Parkinson's disease research conducted at Harvard University and Mass General Brigham. The therapy is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital, with early data demonstrating 29%-62% motor score improvements and neuroimaging evidence of restored dopaminergic signaling.

Differentiator

Problem solved

Functional benefit

Products and services

• Autologous Dopaminergic Neuron Replacement Therapy (Lead Program) An autologous cell therapy in which a patient's own blood cells are reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into midbrain dopaminergic neurons for implantation into the post-commissural putamen. The therapy is intended for Parkinson's disease patients to restore dopaminergic signaling and motor function without the need for chronic immunosuppression, and is currently being evaluated in a Phase 1b/2a clinical trial at Brigham & Women's Hospital.

Quantifiable outcome

• Motor scores decreased 29%–62% from baseline at 6–18 months post-treatment in Phase 1b/2a trial
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Mass General Brigham - Neuroregeneration Institute at McLean HospitalcoreStrategic or Co-development Partner · 23 March 2026Oryon collaborates with the Neuroregeneration Institute at McLean Hospital, part of Mass General Brigham, for its clinical research program. The collaboration involves foundational Parkinson's disease research and current clinical trial execution. Penelope Hallett, Ph.D., Co-Director of the Neuroregeneration Research Institute, serves as principal investigator.
• Brigham & Women's HospitalcoreStrategic or Co-development Partner · 23 March 2026Phase 1b/2a clinical trial is being conducted at Brigham & Women's Hospital/Harvard Medical School for Oryon's lead autologous neuron replacement therapy program.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Sana Biotechnology: Sana Biotechnology is developing engineered cell therapies, including hypoimmune cell transplant approaches, with applications in neurological diseases. Although broader than Oryon's focused Parkinson's program, Sana's cell engineering platform and CNS ambitions make it a relevant comparable for autologous/allogeneic cell therapy platforms targeting the brain.
• Neuron23: Neuron23 is developing precision medicines for Parkinson's disease, including a LRRK2 inhibitor currently in Phase 2. Oryon board member Adam Knight was Neuron23's founder/CEO. Neuron23 competes with Oryon for Parkinson's market share and partnership interest, though via a small-molecule route rather than cell replacement.
• Cerevel Therapeutics: Cerevel Therapeutics (acquired by AbbVie in 2024) developed CNS therapies including Parkinson's disease candidates (e.g., tavapadon). As a CNS-focused clinical-stage biotech, Cerevel is a relevant comparable for fundraising scale, clinical development approach, and large-pharma acquisition interest in Parkinson's assets.
• Century Therapeutics: Century Therapeutics is developing iPSC-derived allogeneic cell therapies for cancer and neurodegenerative diseases, leveraging similar iPSC engineering and differentiation science. Although focused initially on oncology, its iPSC platform and CNS ambitions make it a comparable technology peer for Oryon's autologous iPSC approach.

Direct peers

• Prevail Therapeutics: Prevail Therapeutics (acquired by Eli Lilly in 2020) develops AAV-based gene therapies for neurodegenerative diseases, including PR001 for Parkinson's disease associated with GBA1 mutations. It is a direct competitor addressing Parkinson's neuronal dysfunction via a different modality (gene therapy vs. cell replacement) but the same underlying therapeutic hypothesis.
• Aspen Neuroscience: Aspen Neuroscience is developing autologous iPSC-derived dopaminergic neuron replacement therapies (ANPD001) for Parkinson's disease. It directly competes with Oryon in the autologous iPSC approach for the same indication, targeting a similar patient population and neurosurgical delivery model.
• BlueRock Therapeutics: BlueRock Therapeutics (acquired by Bayer in 2019) is developing iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease, including bemdaneprocel. It is the most direct competitor to Oryon in autologous/allogeneic iPSC-derived neuron replacement for Parkinson's and represents the leading benchmark for this therapeutic approach.

Others

• Roche: Roche has invested in Parkinson's and broader neurodegenerative disease pipelines (including prasinezumab collaborations) and pursues both small-molecule and biologic CNS strategies. Roche represents a relevant large-pharma strategic partner/acquirer with deep neurology presence, rather than a direct competitor to Oryon's cell therapy.

Broad incumbents

• Vertex Pharmaceuticals: Vertex Pharmaceuticals is advancing VX-880, an allogeneic stem cell-derived islet cell therapy, and is building broader cell therapy capabilities that could overlap with Oryon's CNS cell replacement vision. As a large, well-capitalized biopharma, Vertex represents both a competitive threat and a potential strategic acquirer/partnership candidate.
• Acorda Therapeutics: Acorda Therapeutics developed and commercialized INBRIJA and other Parkinson's therapies; Oryon CEO Ron Cohen founded Acorda and Oryon CMO Burkhard Blank was previously CMO there. Acorda is a historical Parkinson's incumbent with directly relevant commercial infrastructure and provides the most directly comparable prior playbook for Oryon's commercialization strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/oryon-cell-therapies

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oryon Cell Therapies